| 产品详情 |
| Edit |   |
|---|
| Product Name | anti-B2glycoprot1 IgG ELISA |
|---|
| Description | The wells of the microtitre strips are coated with highly purified human β2GP1 Antigens. During the first incubation, specific autoantibodies in diluted serum or plasma bind to the Antigens-coated surface. The wells are then washed to remove unbound components. In the second incubation, the Conjugate, enzyme-labelled antibodies to human IgG, binds any surface-bound autoantibodies. After further washing, specific autoantibodies are traced by incubation with the Substrate. Addition of Stop Solution terminates the reaction, resulting in a coloured end-product. The amount of Conjugate bound is measured in absorbance units. In the qualitative protocol, the amount of Conjugate bound by the sample is compared with that bound by the Reference Control. In the quantitative protocol, the concentration of anti-β2GP1 autoantibody can be estimated by interpolation from a dose-response curve based on Standards formulated from a high titre plasma and assigned arbitrary units. Sample Types: serum, plasma. Range: Cutoff. Time: 2 hours • β2-glycoprotein 1 (β2GP1), or apolipoprotein H, is a plasma glycoprotein that circulates at approximately 200µg/mL1. It is associated with plasma lipoproteins, in particular very low-density lipoprotein, and may regulate haemostatic actions occurring on the lipoprotein surface2. β2GP1 has been shown to inhibit the intrinsic coagulation pathway via inhibition of Factor XII activation on negatively charged surfaces2, and is the dominant Antigens for anti-phospholipid antibodies (APAs) in patients with anti-phospholipid syndrome3. The presence of APAs such as anti-cardiolipin antibodies is associated with venous and arterial thrombosis, recurrent spontaneous abortions and thrombocytopaenia. Anti-cardiolipin antibodies are also present in response to a variety of infections and certain drug treatments. APAs associated with infections are usually transient and not associated with thromboembolic complications; APAs in autoimmune disease are often associated with thromboembolic disease4. Although the mechanism of APA binding is poorly understood, it has been demonstrated that APAs may bind directly to phospholipid or via a protein co-factor, most commonly β2GP1. β2GP1 is often included in anti-cardiolipin assays to ensure the detection of both β2GP1-dependent and β2GP1-independent antibodies. β2GP1 dependent APAs tend to be associated with autoimmune disease; β2GP1-independent APAs tend to be associated with infection3,4. A number of studies have demonstrated that detection of β2GP1 antibodies, in conjunction with anticardiolipin measurement, is important in defining the thrombotic risk associated with APAs. β2GP1 IgG antibodies are more closely associated with thrombosis in patients with a history of anti-phospholipid antibody-associated diseases than anti-cardiolipin antibodies5-8. |
|---|
| Size | 1 x 96 well |
|---|
| Concentration | n/a |
|---|
| Applications | RUO |
|---|
| Other Names | eurodiagnostica FBGP 200 anti-Beta2 glycoprotein IgG ASSAY EIA ELISA B2 GP1 Apolipoprotein H |
|---|
| Gene, Accession, CAS # | n/a |
|---|
| Catalog # | FBGP200 |
|---|
| Price | |
|---|
| Order / More Info | anti-B2glycoprot1 IgG ELISA from EAGLE BIOSCIENCES INC. |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|